FIA
REGN icon

Foundations Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Foundations Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-293
Closed -$226K – 1288
2026
Q1 		$226K Buy
+293
New +$224K ﹤0.01% 1051
2021
Q4 		– Sell
-616
Closed -$339K – 353
2021
Q3 		$339K Buy
616
+121
+24% +$75.1K 0.01% 236
2021
Q2 		$287K Buy
+495
New +$251K 0.01% 245

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Foundations Investment Advisors's REGN Position: Q2 2026 in Review

Foundations Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 293 shares — an estimated $226K sold.

Foundations Investment Advisors first reported a position in REGN in Q2 2021 and held it in 3 quarters. The position peaked at $339K in Q3 2021. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Foundations Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Foundations Investment Advisors sold 293 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $226K.
  • Foundations Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Foundations Investment Advisors's Regeneron Pharmaceuticals position peaked at $339K in Q3 2021.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Foundations Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.